(Q38212889)

31 August 2017

title

Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls (English)

1 reference

31 August 2017

0 references

1 reference

Ashish Kumar Kakkar

1

1 reference

31 August 2017

Neha Dahiya

series ordinal

2

1 reference

31 August 2017

publication date

18 April 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

94

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

357-362

1 reference

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Programmes and principles in treatment of multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Global tuberculosis drug development pipeline: the need and the reality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

The challenge of new drug discovery for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Tuberculosis: the drug development pipeline at a glance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Surrogate markers to assess new therapies for drug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2014.04.001

10.1016/J.TUBE.2014.04.001

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference